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Neuropilin-1 (NRP-1) is a novel co-receptor for vascular endothelial growth factor (VEGF). Neuropilin-1 is expressed in pancreatic
cancer, but not in nonmalignant pancreatic tissue. We hypothesised that NRP-1 expression by pancreatic cancer cells contributes to
the malignant phenotype. To determine the role of NRP-1 in pancreatic cancer, NRP-1 was stably transfected into the human
pancreatic cancer cell line FG. Signal transduction was assessed by Western blot analysis. Susceptibility to anoikis (detachment
induced apoptosis) was evaluated by colony formation after growth in suspension. Chemosensitivity to gemcitabine or 5-fluorouracil
(5-FU) was assessed by MTT assay in pancreatic cancer cells following NRP-1 overexpression or siRNA-induced downregulation of
NRP-1. Differential expression of apoptosis-related genes was determined by gene array and further evaluated by Western blot
analysis. Neuropilin-1 overexpression increased constitutive mitogen activated protein kinase (MAPK) signalling, possibly via an
autocrine loop. Neuropilin-1 overexpression in FG cells enhanced anoikis resistance and increased survival of cells by 430% after
exposure to clinically relevant levels of gemcitabine and 5-FU. In contrast, downregulation of NRP-1 expression in Panc-1 cells
markedly increased chemosensitivity, inducing 450% more cell death at clinically relevant concentrations of gemcitabine. Neuropilin-1
overexpression also increased expression of the antiapoptotic regulator, MCL-1. Neuropilin-1 overexpression in pancreatic cancer
cell lines is associated with (a) increased constitutive MAPK signalling, (b) inhibition of anoikis, and (c) chemoresistance. Targeting
NRP-1 in pancreatic cancer cells may downregulate survival signalling pathways and increase sensitivity to chemotherapy.
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Vascular endothelial growth factor (VEGF), one of the best-
characterised proangiogenic factors, plays roles in both normal
and pathologic angiogenesis. In particular, VEGF (VEGF-A, vascular
permeability factor) overexpression has been associated with
tumour progression and poor prognosis in a number of tumour
systems (Dvorak et al, 1995; Takahashi et al, 1995; Fujimoto et al,
1998; Berns et al, 2003; Gorski et al,2 0 0 3 ) .V a s c u l a re n d o t h e l i a l
growth factor’s effects are mediated primarily through two tyrosine
kinase receptors: VEGFR-1 (Flt-1) and VEGFR-2 (Flk-1/KDR). More
recently, two additional nontyrosine kinase receptors for the VEGF
family have been identified, neuropilin-1 (NRP-1) and neuropilin-2,
which are believed to function as co-receptors for VEGFR-1 and
VEGFR-2 (Fuh et al, 2000; Whitaker et al, 2001). Although the VEGF
receptors have been described as endothelial cell-specific, emerging
evidence has documented their presence on tumour cells (Itakura
et al, 2000; Masood et al, 2001). Vascular endothelial growth factor
overexpression has been shown in a number of tumour systems
(Fujimoto et al, 1998; Lee et al, 2000), where it is believed to
function as a paracrine angiogenic factor affecting endothelial cell
signalling; however, the presence of VEGF receptors on tumour cells
raises the possibility of VEGF family members also acting in an
autocrine fashion on the tumour itself.
In neurobiologic studies, the highly conserved glycoprotein
NRP-1 was determined to mediate axonal guidance by forming
complexes with plexins and propagating signals initiated by class 3
semaphorin ligands (Takahashi et al, 1999). Our laboratory and
others have shown that NRP-1 is overexpressed in a variety of
pancreatic tumour specimens and cell lines but not in nonmalig-
nant pancreatic tissue (Parikh et al, 2003; Fukahi et al, 2004;
Hansel et al, 2004). However, the functional significance of NRP-1
on tumour cells has not been elucidated.
We hypothesised that NRP-1 expression on pancreatic cancer
cells contributes to the malignant phenotype. In this study, we
overexpressed NRP-1 in a human pancreatic cell line (FG) with
relatively low endogenous expression of NRP-1 and assessed the
effects on downstream signalling pathways, detachment-induced
apoptosis (anoikis), and chemoresistance. In a complementary
experiment, we downregulated NRP-1 expression by small
interfering RNA (siRNA) in a cell line with relatively high NRP-1
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sexpression (Panc-1) and evaluated the effect of decreased NRP-1
expression on chemosensitivity. Neuropilin-1 overexpression in
FG cells was found to increase constitutive mitogen-activated
protein kinase (MAPK) signalling via both the extracellular signal-
regulated kinase (ERK) and c-Jun NH2-terminal kinase (JNK)
pathways, to enhance survival of cells grown in suspension, and to
increase resistance to two chemotherapeutic agents. Furthermore,
decreasing NRP-1 expression in Panc-1 cells enhanced their
susceptibility to chemotherapy. Analysis of apoptosis-related gene
expression by gene array also demonstrated that NRP-1 over-
expression was associated with induction of the antiapoptotic
regulator, MCL-1.
MATERIALS AND METHODS
Materials
Antibodies for Western blotting, immunoprecipitation (IP), and
fluorescence-activated cell sorting (FACS) were as follows:
polyclonal rabbit anti-phospho-ERK1/2 (p42/44) (Thr202/Tyr204;
Cell Signaling Technology, Beverly, MA, USA), polyclonal rabbit
anti-phospho-Akt (Ser473; Cell Signaling Technology), polyclonal
rabbit anti-JNK (Thr183/Tyr185; Cell Signaling Technology),
polyclonal rabbit anti-MAPK (Erk-1/2) (Oncogene Research
Products, Cambridge, MA, USA), polyclonal rabbit anti-Akt (Cell
Signaling Technology), monoclonal rabbit anti-JNK (56G8; Cell
Signaling Technology), monoclonal mouse anti-NRP-1 (A-12;
Santa Cruz Biotechnology, Santa Cruz, CA, USA), polyclonal
rabbit anti-NRP-1 (H-286; Santa Cruz Biotechnology), polyclonal
goat anti-SEMA3a (C-17) antibody (Santa Cruz Biotechnology),
monoclonal mouse anti-vinculin (Sigma, St Louis, MO, USA),
polyclonal rabbit anti-DFF45 (BD Biosciences, San Diego, CA,
USA), monoclonal mouse anti-MCL-1 (22; Santa Cruz Biotechno-
logy), fluorescein isothiocyanate (FITC)-conjugated goat anti-
rabbit immunoglobulin G (IgG) (Jackson ImmunoResearch, West
Grove, PA, USA), horseradish peroxidase (HRP)-conjugated sheep
anti-mouse (Amersham Biosciences, Piscataway, NJ, USA), HRP-
conjugated goat anti-rabbit (Bio-Rad Laboratories, Hercules, CA,
USA), and HRP-conjugated rabbit anti-goat (Jackson ImmunoR-
esearch). The chemotherapeutic agents gemcitabine (difluoro-
deoxycytidine) (Eli Lilly, Indianapolis, IN, USA) and 5-fluorouracil
(5-FU) (50mgml
 1 aqueous; American Pharmaceutical Partners,
Schaumberg, IL, USA) were purchased from The University of
Texas MD Anderson Cancer Center Pharmacy. Protein A/G
agarose beads were purchased from Santa Cruz Biotechnology.
Chemicals utilised were purchased from Sigma unless otherwise
indicated.
Cell lines and culture conditions
The FG cell line was originally established from COLO 357 human
pancreatic cancer cells by Vezeridis et al (1990) and was kindly
provided by IJ Fidler, PhD, DVM (The University of Texas MD
Anderson Cancer Center, Houston, TX, USA). Panc-1 human
pancreatic cancer cells were purchased from the American Type
Culture Collection (Manassas, VA, USA). Cells were cultured and
maintained in supplemented minimal essential medium (MEM)
as previously described (Jung et al, 1999). Transfected cells were
maintained in medium supplemented with 200mgml
 1 G418
(neomycin; Life Technologies). In vitro experiments were
performed at 60–80% cell confluence, and cells were used at
passages 3–15 after their receipt from the supplier or transfection.
Stable transfection of NRP-1
The full-length human NRP-1 cDNA (Soker et al, 1998) was
subcloned into the pcDNA3.1 vector (Invitrogen, Carlsbad, CA,
USA) by standard techniques. Orientation was confirmed by
restriction enzyme analysis and DNA sequencing. The resulting
vector was stably transfected into human FG and Panc-1
pancreatic cancer cell lines using the FuGENE 6 transfection
reagent (Roche Diagnostics Corporation, Indianapolis, IN, USA)
according to the manufacturer’s protocol. Control cells were
transfected with the native pcDNA3.1 vector (mock transfectants).
After 48h, the medium was replaced by selective medium
containing 400mgml
 1 G418. Clones were expanded, and success-
ful transfection was confirmed by Western blot analysis using anti-
NRP-1 antibodies (see below). Clones #1 and #9 expressed the
highest levels of NRP-1 and were selected for further study.
Creation of NRP-1 siRNA plasmids and cell lines
SiRNA expression plasmids were created using the pSilencer 1.0-
U6 vector (Ambion, Austin, TX, USA) according to the manu-
facturer’s directions. Neuropilin-1-specific target sequences were
developed and designed using the Ambion siRNA web design tool.
The two target sequences utilised were 50-AAGCTCTGGGCATGG
AATCAG-30 and 50-AAAGCCCCGGGTACCTTACAT-30. Corre-
sponding oligonucleotides with terminal Apa1 (50) and R1 (30)
restriction sites were purchased from Invitrogen and ligated into
the expression plasmid at compatible sites. Isolated clones were
confirmed by DNA sequencing. Cell lines expressing decreased
NRP-1 levels were created by transfecting Panc-1 cells with 0.5ng
of each of the siRNA plasmids and 10ng of pcDNA G418-resistance
promoter-less plasmid and selected in medium containing G418
as described above. Control cells were similarly transfected with
scrambled NRP-1 target sequences and pcDNA plasmids. Neuro-
pilin-1 expression levels in siRNA-transfected clones were
determined by IP and Western blot analysis (see below). Clones
#1 and #2 were shown to express o10% of baseline NRP-1 and
were selected for further study.
Fluorescence-activated cell sorting analysis of NRP-1-
transfected cells
Cells were washed with phosphate-buffered saline (PBS) and
detached with 0.1%. EDTA. Polyclonal rabbit anti-NRP-1 antibody
(H-286) was added at 4mgmillion
 1 cells, and cells were incubated
on ice for 30min. Cells were washed with cold PBS and incubated
with FITC-conjugated goat anti-rabbit IgG at 7.5mgmillion
 1 cells
for 30min on ice. Cells were washed, fixed in 1% paraformalde-
hyde, and analysed on an Epics XL-MCL flow cytometer
(Beckman-Coulter, Miami, FL, USA). Positive staining (þ)i s
designated as the % staining above background.
Immunoprecipitation/Western blot hybridisation for NRP-1
Cells were lysed with RIPA-B protein lysis buffer (Parikh et al,
2003). Protein was quantitated by a commercially available
modified Bradford assay (Bio-Rad protein assay, Bio-Rad Labora-
tories). For IP, 500mg of protein was preincubated for 1h at
41C with protein A/G agarose beads. Polyclonal rabbit anti-NRP-1
antibody (H-286) was then added at a 1:100 dilution and
incubated at 41C overnight with rotation. Immunoprecipitation
samples were boiled with denaturing sample buffer for 5min, and
proteins were separated by sodium dodecyl sulphate–polyacryla-
mide gel electrophoresis (SDS–PAGE) on a 6% denaturing
polyacrylamide gel and transferred onto a polyvinylidene difluo-
ride (PVDF) membrane (Millipore Corp., Bedford, MA, USA) as
previously described (Jung et al, 1999). Western blot samples
utilised 50mg of protein from cell lysates, which were also boiled
with denaturing sample buffer before electrophoresis. After
blocking with 5% nonfat dry milk in Tris-buffered saline contain-
ing 0.1% Tween-20 (TBS-T), the membranes were probed with a
monoclonal mouse anti-NRP-1 antibody (A-12) at a 1:200 dilution
in 5% milk-TBS-T overnight at 41C. The membranes were washed
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sand incubated with an appropriate HRP-conjugated secondary
antibody, and protein bands were visualised using a commercially
available enhanced chemiluminescence (ECL) kit (Amersham
Biosciences).
Analysis of effect of NRP-1 transfection on signalling
Cells were grown to 60–70% cell confluence and incubated
overnight in medium containing 5% FBS. Samples were prepared
as described above. Activated signalling pathways were identified
by incubation with polyclonal rabbit anti-phospho-ERK1/2,
anti-phospho-JNK, or anti-phospho-Akt antibodies at a 1:1000
dilution in 5% milk-TBS-T. To verify accuracy of loading,
membranes were stripped as previously described (Jung et al,
1999) and probed with anti-Erk-1/2, anti-JNK, or anti-Akt
antibodies at a 1:1000 dilution in 5% milk-TBS-T. Detection of
bands by ECL was performed using a secondary HRP-conjugated
goat anti-rabbit antibody. Quantitative comparison of phosphory-
lated signalling intermediates was carried out by densitometric
analysis of scanned images (NIH Image 1.63).
Analysis of effect of conditioned medium from
NRP-1-transfected cells on signalling
NRP-1-transfected or mock transfected FG cells were plated at 1
million cells/10cm dish and incubated with 1% FBS-MEM for
48h. Conditioned medium was then collected and centrifuged
at 1000r.p.m. for 5min. Mock-transfected FG cells were plated
at 60–70% confluence, and medium was changed to 1% FBS-MEM
for overnight incubation. Mock-transfected cells were then treated
for 5 or 15min with conditioned medium from NRP-1 or mock
transfectants. Cells were then lysed in RIPA-B lysis buffer, and
Western blot analysis was performed as described above.
Assessment of NRP-1 ligand production
Expression levels of the NRP-1 ligands VEGF and semapho-
rin3a (SEMA3a) by FG cells were investigated in order to assess
for the possibility that NRP-1 overexpression could lead to
induction of NRP-1 ligands, thus augmenting an autocrine
loop. A human VEGF ELISA kit (R&D Systems, Minneapolis,
MN, USA) was used to evaluate VEGF production in the
conditioned medium and lysates from NRP-1 and mock trans-
fected FG cells, according to the manufacturer’s protocol. SEMA3a
secretion was evaluated by Western blot of conditioned medium
from transfected FG cells, utilising anti-SEMA3a antibody at a
1:200 dilution.
Analysis of detachment-induced apoptosis (anoikis)
After NRP-1-transfected and mock-transfected FG cells were
trypsinised, 1000 cells were either immediately plated in 10%
MEM or grown in suspension for 48h by rotation in a 15ml Falcon
tube with filter cap (BD Biosciences, Bedford, MA, USA) at 371Ci n
a standard incubator and then plated. Both suspended and
non-suspended cells were allowed to grow for 1 week after plating.
Colonies containing 10 or more cells were then counted on a grid,
and the average of eight fields was calculated. Colony formation
after growth in suspension was calculated as the percentage of such
colonies formed relative to colonies formed by cells not subjected
to growth in suspension.
Analysis of effect of NRP-1 transfection on
chemosensitivity
Transfected FG or Panc-1 cells (3–4 10
3) were plated in 96-well
plates. Following cell attachment after 24h, medium was changed
to 10% FBS-MEM with various concentrations of either gemcita-
bine or 5-FU, and cells were incubated for 24 or 48h. Gemcitabine
was reconstituted to 1mM in PBS immediately prior to use. In
order to quantitate surviving/proliferating cells, 0.5mgml
 1 of
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide
(MTT) was added and incubated for an additional 90min. Medium
and MTT were removed, dimethyl sulphoxide was added for
1min to solubilise cells, and absorption was read at 570nm in a
spectrophotometer. In each experiment, cells were plated in
quadruplicate and the average of the relative absorption (OD570)
was used as an estimate of the number of metabolically active cells.
Percentage of treated cells surviving compared to control cells
not exposed to chemotherapy was calculated from the average
OD570 values obtained in each experiment. Each experiment was
performed at least in triplicate for statistical analysis. Analysis and
graphing were performed utilising Sigmaplot 8.0 (SPSS Science
Marketing Dept. Chicago, IL, USA).
Analysis of apoptosis-related gene expression by
SuperArray
Total RNA was extracted from subconfluent mock-transfected
(pcDNA pool) and NRP-1-transfected (clone #1) FG cells using
RNeasy Mini Spin Columns (QIAGEN, Valencia, CA) according
to manufacturer’s protocol. Biotin-labelled cDNA probes were
prepared using the AmpoLabeling-LPR Kit (SuperArray, Frederick,
MD, USA) and hybridised to the GEArray Q series Human
Apoptosis Gene Array (SuperArray), according to the manufac-
turer’s protocol. After chemiluminescent detection, data were
analysed using ScanAlyze (www.rana.lbl.gov/EisenSoftware.htm;
Eisen laboratory, Stanford University) and GEArray Analyzer
software (SuperArray) in order to quantitate and normalise
relative levels of gene expression. Protein expression of DFF45
and MCL-1 was assessed by Western blot analysis and densito-
metry as described above, utilising anti-DFF45 antibody (1:500
dilution) and anti-MCL-1 antibody (1:100 dilution) in 5% milk-
TBS-T. Actin was used as a loading control.
RESULTS
NRP-1 overexpression by transfection in FG cells
Given the observation that NRP-1 is expressed at higher levels
in pancreatic tumours than in normal pancreatic tissue
(Parikh et al, 2003), we first chose to study the effect of
overexpression of NRP-1 in a cell line with relatively low
endogenous expression, the FG human pancreatic carcinoma
cell line. Immunoprecipitation/Western blot analysis demon-
strated high levels of NRP-1 expression in NRP-1-transfected
FG cells compared to parental or mock-transfected FG cells
(Figure 1A). To confirm these findings, FACS analysis was
also performed and confirmed a two- to five-fold increase in
NRP-1 expression in transfected cells compared to control cells,
based upon the percentage of cells expressing NRP-1 above
background levels (Figure 1B). Similar results were confirmed after
repeating experiments several times.
Constitutive signalling in NRP-1-overexpressing FG cells
The functionality of the overexpressed NRP-1 protein was
then assessed for activation of downstream signalling inter-
mediates. Compared to mock transfectants, NRP-1 transfectants
demonstrated a 4six-fold increase in constitutive ERK1/2
and 4four-fold increase in constitutive JNK phosphorylation
(Figure 2). In contrast, no differences were detected in phos-
phorylated Akt levels (data not shown). These findings were
confirmed in repeat studies.
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sEffect of conditioned medium from NRP-1-transfected
cells on signalling
Since NRP-1 overexpression resulted in such a consistent increase
in ERK1/2 and JNK signalling, we sought to determine whether this
was caused by induction of an autocrine pathway. Conditioned
medium from mock-transfected or NRP-1-transfected FG cells was
collected and applied to mock-transfected FG cells, and the effect
on signalling intermediates was assessed. Nearly a two-fold
induction of ERK1/2 phosphorylation was consistently detected
in cells exposed to conditioned medium from NRP-1-overexpres-
sing cells, and a greater than three-fold increase was seen in JNK
phosphorylation, similar to levels seen in NRP-1-overexpressing
cells themselves (Figure 3). Low levels of phosphorylated ERK1/2
and JNK were seen in control cells grown in 1% medium (data not
shown). These findings suggest that the upregulated MAPK
signalling observed in NRP-1-overexpressing cells is due to an
autocrine pathway regulated by a secreted factor.
Since VEGF-A is a major ligand for NRP-1, VEGF-A levels
were evaluated in cell supernatants and lysates by enzyme-
linked immunosorbent assay. Although VEGF-A levels were
slightly higher in lysates from NRP-1-transfected FG cells
than in mock transfectants, the level of secreted VEGF-A
in conditioned medium from NRP-1 transfectants was approxi-
mately 25% lower than in conditioned medium from mock-
transfected controls (data not shown), suggesting that VEGF-A
is unlikely to be solely responsible for the observed signal-
ling alterations. Expression of semaphorin-3a (SEMA3a),
the natural ligand for NRP-1 in the nervous system, was also
assessed in NRP-1-transfected FG cells by Western blot analysis,
and its levels were unchanged by NRP-1 overexpression (data not
shown). Thus, NRP-1 overexpression appears to induce MAPK
signalling, at least in part via an autocrine pathway, although the
mediator of this does not appear to be solely dependent on VEGF
or SEMA3a.
Effect of NRP-1 overexpression on susceptibility to anoikis
Since the MAPK/ERK pathway has been associated with increased
survival of cells and anoikis resistance in some systems (Fukazawa
et al, 2002), we were interested in determining how its induction
affects the ability of FG cells to survive particular stressors. Normal
epithelial cells subjected to loss of substrate adherence undergo
apoptosis in a process known as anoikis (Frisch and Francis, 1994).
This apoptotic response is often lost in cancer cells (Swan et al,
2003), and this loss may facilitate their ability to survive
detachment and to implant elsewhere as a metastasis. Control FG
cells and NRP-1-overexpressing FG cells were plated either after
standard substrate-adherent growth or after 48h of incubation in
suspension. Survival was assayed by colony formation after 1 week
of adherent growth. In contrast to mock-transfected cells, which
only formed about half as many colonies per cm
2 after growth in
suspension, both NRP-1-overexpressing clones formed equal
numbers of colonies, with or without being subjected to growth
in suspension (Po0.0001) (Figure 4). These findings suggest that
NRP-1 overexpression provides cells with a survival advantage
when they lose substrate attachment.
Effect of NRP-1 overexpression on chemosensitivity of FG
cells
NRP-1 overexpression enhanced the resistance of FG cells to
anoikis; therefore, we hypothesised that NRP-1 overexpression
also promoted survival of cells exposed to other stressors. The role
of NRP-1 expression in mediating chemoresistance was of
particular interest, since most chemotherapeutic agents have
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Figure 1 Effect of NRP-1 transfection on NRP-1 levels in FG cells. (A) Immunoprecipitation and Western blot analysis of lysates from mock-transfected
(pool and C#1) and NRP-1-transfected clones (NRP-1 C#1 and C#9) confirmed overexpression of NRP-1 in transfectants. (B) FACS analysis using a
polyclonal rabbit anti-NRP-1 antibody (H-286) demonstrated a two- to five-fold increase in NRP-1 expression in NRP-1-transfected cells. Data shown are
representative of results from multiple experiments.
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slimited efficacy in patients with pancreatic cancer. We focused our
studies on the effects of gemcitabine on pancreatic cancer cells in
vitro, as this agent is approved for clinical use by the US Food and
Drug Administration. After 24h of gemcitabine exposure, MTT
assay demonstrated improved survival in both NRP-1-overexpres-
sing clones relative to the mock transfectants at doses around
100nM, near the 50% inhibitory concentration (IC50) of gemcita-
bine in FG cells (Po0.03) (Figure 5A). An IC50 dose was not
achieved in the NRP-1 transfected cells at this time point, even at
supratherapeutic doses. The survival advantage was even more
dramatic (Pp0.005) at 50000nM, a therapeutically relevant
concentration within the range of the peak plasma levels achieved
following bolus gemcitabine chemotherapy (De Pas et al, 2000;
Fogli et al, 2002). At this dose, at least 30% more of the NRP-1-
transfected cells survived compared to control cells. At 48h, the
majority of all cells were nonviable, and no statistically significant
difference between NRP-1-transfected and mock-transfected cells
was observed (data not shown).
To verify that this chemoresistance was not a phenomenon
unique to gemcitabine, studies were repeated using 5-FU, a
different chemotherapeutic agent often used in treatment of
pancreatic cancer. Again at 24h, NRP-1 overexpression afforded
cells a greater than 40% improvement in survival at doses near the
IC50 (25mgml
 1)( Po0.005) (Figure 5B), which also approxi-
mates the peak plasma levels of 5-FU achieved during chemo-
therapy (Bocci et al, 2000). The statistically significant survival
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Figure 4 Increased resistance of NRP-1-transfected FG cells to anoikis.
Neuropilin-1-overexpressing cells (NRP-1 C#1 and C#9) or mock
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were performed at least in duplicate; graph shown is representative of
findings.
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sdifference persisted at 48h after exposure to this agent (data not
shown).
Effect of NRP-1 knockdown on chemosensitivity in Panc-1
cells
Having demonstrated that NRP-1 overexpression provides a
survival advantage for FG cells exposed to two chemo-
therapeutic agents, we sought to determine whether decreased
NRP-1 expression would render pancreatic cancer cells more
susceptible to these drugs. Since FG cells express relatively
low levels of NRP-1 at baseline, we utilised the Panc-1 cell line,
a human pancreatic cancer cell line with endogenously high
levels of NRP-1 to develop clones with downregulated NRP-1
expression, utilising siRNA technology. Western blot analysis and
densitometry indicated that siRNA-transfected clones expressed
NRP-1 protein at less than 10% of endogenous levels (Figure 6A).
Using stable transfection of NRP-1, we also developed clones with
at least two-fold higher levels of NRP-1 than parental or mock
transfectants.
Both the NRP-1-overexpressing and siRNA clones were
then assayed for chemosensitivity to gemcitabine and 5-FU by
MTT assay. SiRNA-transfected Panc-1 cells proved to be
much more susceptible to gemcitabine at both 24 and 48h
compared to NRP-1-overexpressing clones, which demon-
strated almost no sensitivity to chemotherapy. At the thera-
peutically relevant dose of 50000nM, the difference in survival
following gemcitabine treatment between NRP-1-overexpressing
cells and cells with decreased NRP-1 expression was 450%
and highly significant (Po0.001) (Figure 6B). In fact, even
at supratherapeutic levels of gemcitabine, the IC50 dose was
not achieved in the NRP-1 transfectants. Similarly, NRP-1
downregulation by siRNA rendered the Panc-1 cells more
susceptible to treatment by 5-FU compared to NRP-1 transfectants
(Po0.05) at the clinically relevant dose of 25mgml
 1 (data not
shown). The susceptibility of parental Panc-1 cells varied from
experiment to experiment but remained intermediate relative to
that of either the NRP-1-overexpressing or knockout clones (data
not shown).
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Figure 5 Promotion of chemoresistance by NRP-1. (A) NRP-1-
transfected or mock-transfected FG cells were plated on a 96-well plate
and treated with various doses of gemcitabine. After incubation for 24h,
cell survival was assessed by MTT assay. At concentrations of gemcitabine
similar to peak plasma levels after bolus chemotherapy (50000nM,
indicated by dashed line), NRP-1-overexpressing cells demonstrated
greater chemoresistance (higher survival rate) compared to controls
(Pp0.005). Filled squares, mock-transfected pool; filled circles, NRP-1
clone #1 (C#1); open triangles, NRP-1 clone #9 (C#9); *Po0.05. (B)
NRP-1-transfected or mock-transfected FG cells were plated on a 96-well
plate and treated with various doses of 5-FU. After incubation for 24h, cell
survival was assessed by MTT assay. At concentrations of 5-FU similar to
peak plasma levels after bolus chemotherapy (25mgml
 1, indicated by
dashed line), NRP-1-overexpressing cells demonstrated greater chemo-
resistance (higher survival rate) compared to controls (Po0.005). Similar
results were seen at 48h (not shown). Filled squares, mock-transfected
pool; filled circles, NRP-1 clone #1 (C#1); open triangles, NRP-1 clone #9
(C#9); *Po0.05.
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Figure 6 Association of NRP-1 levels with chemoresistance to
gemcitabine in Panc-1 transfectants. (A) Panc-1 cells were transfected
with full-length NRP-1, siRNA directed against NRP-1, or mock-transfected
control vectors (pcDNA). Selected clones were screened for NRP-1
expression by Western blot analysis using either a polyclonal or
monoclonal anti-NRP-1 antibody. Relative levels of NRP-1 expression
were compared by densitometry. Neuropilin-1-transfected clones with at
least two-fold overexpression were selected for further study. Selected
clones (C#1 and #2) with functional siRNA demonstrated a decrease in
NRP-1 expression by 490% and were selected for further study. Mock-
transfected cells demonstrated levels of NRP-1 expression similar to those
in parental cells. (B) NRP-1-transfected, mock-transfected, and siRNA-
transfected (NRP-1-depleted) Panc-1 cells were plated on a 96-well plate
and treated with various doses of gemcitabine. After incubation for 24h,
cell survival was assessed by MTT assay. At concentrations of gemcitabine
similar to peak plasma levels after bolus chemotherapy (50000nM,
indicated by dashed line), siRNA-transfected cells with low levels of
NRP-1 (C#1 and C#2) were significantly more susceptible to chemo-
therapy compared to NRP-1-overexpressing cells (Pp0.001). Mock-
transfected control cells demonstrated chemoresistance that varied (not
significantly) by experiment but remained at levels between those of NRP-
1-overexpressing and NRP-1-depleted siRNA-transfected cells (data not
shown). Similar effects were seen at 48h (not shown). Filled circles, NRP-1
transfectant; open triangles, siRNA transfectant C#1; filled squares, siRNA
transfectant C#2; *Po0.006.
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expression
Since the previous experiments demonstrated an association
between NRP-1 and apoptosis resistance, we hypothesised that
NRP-1 expression might induce changes in genes associated with
regulation of apoptosis. Comparison of gene expression between
FG-NRP-1 transfectants and mock transfectants by a commercial
apoptosis-related gene microarray kit and associated analysis
software demonstrated more than 25 genes with a greater than
two-fold change in expression level (data not shown); however, the
most striking NRP-1-induced changes were noted in two
antiapoptotic genes: DNA fragmentation factor 45/alpha (DFF45),
which exhibited a four-fold increase, and a Bcl-2 homologue,
myeloid cell leukemia sequence 1 (MCL-1), which exhibited a
three-fold increase in gene expression level.
In order to confirm these findings, Western blot analysis of the
FG-NRP-1 and mock-transfected cells was carried out to assess
relative protein expression levels of DFF45 and MCL-1. While
DFF45 protein levels were relatively similar in NRP-1 over-
expressing cells and controls (data not shown), MCL-1 protein
levels were nearly two-fold higher in NRP-1-transfected cells
(Figure 7). The reproducibility of MCL-1 induction by NRP-1
overexpression and the significance of this gene on survival/
chemoresistance in other cell lines have yet to be determined.
DISCUSSION
The importance of NRP-1 as a functional receptor in neurobiology
is well established, but its role in tumour biology has only recently
been recognised. This study provides evidence that altering the
level of NRP-1 in pancreatic cancer cell lines causes functional
changes relevant to tumour cell survival. Overexpression of NRP-1
in the FG human pancreatic cell line led to induction of both the
ERK1/2 and JNK signalling pathways, possibly in an autocrine
fashion, as the conditioned medium from NRP-1-overexpressing
cells also increased phosphorylated-ERK1/2 and JNK in control
cells. We also demonstrated that NRP-1 overexpression in the FG
cell line enhanced cell survival following growth in suspension and
exposure to the chemotherapeutic agents, gemcitabine and 5-FU.
Correspondingly, downregulating NRP-1 levels by siRNA in the
Panc-1 cell line led to increased susceptibility to gemcitabine
relative to cells overexpressing the protein. Preliminary data by
microarray suggest that NRP-1 may lead to induction of
antiapoptotic genes, including MCL-1.
Our interest in NRP-1 originated from earlier studies demon-
strating its function as a co-receptor for VEGFR-2, facilitating
VEGFR-2 binding of VEGF165 in endothelial and enhancing cell
migration (Soker et al, 1998). In a prostate cancer model,
transfection of NRP-1 increased VEGF165 binding, basal cell
motility, and tumour size in vivo (Miao et al, 2000), suggesting
that the receptor functions in a VEGF-dependent fashion to
enhance tumorigenicity. However, the survival effects demon-
strated in our study occurred in two cell lines that do not express
VEGFR-2, although they do express VEGFR-1. While NRP-1/
VEGFR-1 interactions may occur, the addition of a VEGFR-1
blocking antibody did not enhance the chemosensitivity of NRP-1-
transfected or mock-transfected cells (data not shown), suggesting
that VEGFR-1 is not essential for this chemoresistance phenom-
enon. Moreover, the use of soluble VEGFR-1 and bevacizumab
(humanised anti-VEGF antibody; Genentech, South San Francisco,
CA, USA) had only a minor effect on cell signalling and survival.
Indeed, more recent studies suggest that NRP-1 functions in
tumour cells other than as a VEGFR co-receptor. One such study
demonstrated that VEGF acted as an autocrine survival factor for
NRP-1-expressing breast cancer cells, protecting them from
hypoxia-induced apoptosis in the absence of VEGFR-2 expression
through activation of the phosphatidylinositol 30-kinase pathway
(Bachelder et al, 2001). Neuropilin-1 has also been implicated in
chemotaxis of breast cancer cell lines through autocrine pathways
involving both VEGF and SEMA3a by complexing with plexin-A1
(Bachelder et al, 2003). Interestingly, whereas the short 40 amino-
acid intracellular domain had previously been thought to be
incapable of independent signalling, one study utilising chimeric
NRP-1 suggests that the intracellular domain of NRP-1 alone may
mediate VEGF-dependent migration in endothelial cells (Wang
et al, 2003). Thus, the mechanisms by which NRP-1 induces
functional changes in tumour cells require further elucidation.
In addition to a VEGFR-independent function of NRP-1, our
studies also implicate a novel ligand for NRP-1, other than the
traditional ligands, VEGF and SEMA3a. Our conditioned medium
studies show that a soluble factor produced by NRP-1 over-
expressing cells activates MAPK signalling in control cells,
although neither of the traditional NRP-1 ligands, VEGF-A and
SEMA3a, were shown to be upregulated in NRP-1 transfected cells
(data not shown). Moreover, addition of recombinant VEGF165 or
SEMA3a did not induce a significant increase in phosphorylated
ERK1/2 and JNK in mock-transfected or parental cells, nor did
they alter the chemoresistance of the NRP-1-transfected or mock-
transfected cells in our study (data not shown). Thus, the
possibility of a novel VEGF-independent and semaphorin-inde-
pendent NRP-1 function remains. This is of particular interest,
since the soluble factors secreted by NRP-1 expressing cells may
enable them to influence the survival of adjacent cells without
NRP-1 overexpression in a paracrine fashion. The identity of this
factor remains to be determined.
The mechanisms by which NRP-1 induces chemoresistance may
be multifactorial. Although the increased proliferative rate of
cancer cells is one reason for their susceptibility to chemotherapy,
this alone is unlikely to have caused the significant differences in
chemosensitivity observed between NRP-1-transfected and mock-
transfected cells, since NRP-1 transfection caused only a slight
decrease in proliferation relative to mock transfection (o30%;
data not shown). Recent studies have demonstrated induction of
signalling pathways specifically associated with gemcitabine
resistance in pancreatic carcinoma. Nuclear factor-kB (NF-kB) is
one such factor whose constitutive activation has been associated
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Figure 7 Effect of NRP-1 overexpression on the antiapoptotic protein,
MCL-1. Analysis of apoptosis-related gene expression by gene microarray
revealed a three-fold increase in gene expression of the antiapoptotic Bcl-2
homologue, MCL-1. In order to confirm upregulation of the MCL-1 protein,
Western blot analysis of the FG mock transfectants and NRP-1
transfectants was performed. A nearly two-fold increase in MCL-1 protein
expression was observed in the NRP-1-overexpressing cells. Actin levels
are shown as a loading control.
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et al, 2003). In our studies, activation of NF-kB (as shown by
nuclear translocation) did not occur, as NRP-1-transfected and
mock-transfected cells showed identical patterns of NF-kB nuclear
and cytoplasmic localisation (data not shown). Others studies have
shown that phosphorylation of the Src nonreceptor tyrosine kinase
is associated with inherent or acquired gemcitabine resistance in
pancreatic cancer cells (Duxbury et al, 2004); however, we detected
no differences in phosphorylated Src between NRP-1-transfected
and mock-transfected FG cells (data not shown). Thus, our
observation of NRP-1-mediated chemoresistance is likely to occur
via an alternative pathway yet to be determined.
Chemoresistance may, in fact, be one of several consequences
of induction of MAPK signalling cascades. Our studies
showed increased constitutive ERK1/2 and JNK signalling as a
consequence of NRP-1 overexpression. Activation of ERK
(Fukazawa et al, 2002; Subauste et al, 2004) or JNK signalling
(Yang et al, 2003; Curtin and Cotter, 2004; Yu et al, 2004)
in association with apoptosis resistance/cell survival is well
documented in the literature in a variety of model systems.
Moreover, at least one study has demonstrated that inhibition of
ERK signalling in pancreatic cancer cell lines leads to down-
regulation of Bcl-2 and other antiapoptotic proteins, including
MCL-1 (Boucher et al, 2000). Thus, NRP-1-induced activation of
these MAPK signalling cascades may promote survival by
induction of downstream apoptotic regulators, including MCL-1,
as observed in our studies. Interestingly, at least one other study
has noted that altered regulation of apoptosis-regulating genes
including MCL-1 appears to be associated with acquired chemore-
sistance of pancreatic cancer cells (Shi et al, 2002). While our
studies of NRP-1 and MCL-1 have only yielded very preliminary
data in one cell line, the possibility of pathways linking NRP-1,
signal transduction, antiapoptotic proteins, and cell survival are
intriguing. Further identification of apoptotic regulators whose
gene expression is altered by NRP-1 transfection may be
warranted.
In summary, this study demonstrates that overexpression of
NRP-1 in a pancreatic cancer cell line increased MAPK signalling
through both the ERK and JNK pathways in an autocrine fashion.
These pathways appear to promote survival of the pancreatic
cancer cell line, specifically against anoikis and chemotherapy-
induced apoptosis, possibly through induction of anti-apoptotic
regulators. Although results of in vitro assays cannot be directly
extrapolated to clinical response owing to the complexity of
tumour biology in humans, our findings may have therapeutic
implications. Since anoikis resistance may correlate with the ability
of cells to survive detachment from the primary tumour mass and
proliferate after migration to a distant site, targeting NRP-1 may
increase anoikis in tumour cells and thereby decrease formation of
metastases. Furthermore, the possibility of targeting therapies to
decrease the level or function of NRP-1 in NRP-1-overexpressing
tumours may lead to enhanced chemosensitivity in a previously
chemoresistant tumour. In addition, the association between NRP-
1 levels and these apoptosis-resistance characteristics may enable
NRP-1 to be used as a prognostic marker. The elucidation of the
role of NRP-1 in tumour biology remains at an early stage, but the
use of NRP-1 as a prognostic factor and/or therapeutic target holds
promise.
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